(19)
(11) EP 1 629 009 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
18.04.2012 Bulletin 2012/16

(45) Mention of the grant of the patent:
14.03.2012 Bulletin 2012/11

(21) Application number: 04735923.7

(22) Date of filing: 03.06.2004
(51) International Patent Classification (IPC): 
C07K 16/08(2006.01)
C07K 16/14(2006.01)
C07K 16/18(2006.01)
 C07K 16/12(2006.01)
C07K 16/16(2006.01)
A61P 31/00(2006.01)
(86) International application number:
PCT/GB2004/002351
(87) International publication number:
WO 2004/106376 (09.12.2004 Gazette 2004/50)

(54)

COMPOSITIONS COMPRISING LARGE AND SMALL BINDING FRAGMENTS OF ANTIBODIES AGAINST THE SAME TOXIN

ZUSAMMENSETZUNGEN DIE GROSSE UND KLEINE GEGEN DAS SELBE TOXIN GERICHTETE ANTIKKÖRPERFRAGMENTE ENTHALTEN

COMPOSITIONS COMPRENANT DE GRANDS ET DE PETITS FRAGMENTS DE LIAISON D'ANTICORPS DIRIGES CONTRE LA MEME TOXINE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

(30) Priority: 03.06.2003 GB 0312642

(43) Date of publication of application:
01.03.2006 Bulletin 2006/09

(73) Proprietor: THE SECRETARY OF STATE FOR DEFENCE
Salisbury Wiltshire SP4 0JQ (GB)

(72) Inventors:
  • HOLLEY, Jane Louise
    Salisbury, Wiltshire SP4 0JQ (GB)
  • MAYERS, Carl Nicholas
    Salisbury, Wiltshire SP4 0JQ (GB)
  • WHITFIELD, David
    Salisbury, Wiltshire SP4 0JQ (GB)
  • BROOKS, Timothy John Gilby
    Salisbury, Wiltshire SP4 0JQ (GB)

(74) Representative: Farnsworth, Alastair Graham et al
DIPR Formalities Section Oak 2E Nr.6228 Abbey Wood (North)
Bristol BS34 8JH
Bristol BS34 8JH (GB)


(56) References cited: : 
   
  • MAYER-CN ET AL.: "Antitoxin therapy for botulinum intoxication" REVIEWS IN MEDICAL MICROBIOLOGY, vol. 12, no. 1, January 2001 (2001-01), pages 29-37, XP002299273
  • MULLER B H ET AL: "Phage-displayed and soluble mouse scFv fragments neutralize rabies virus." JOURNAL OF VIROLOGICAL METHODS. SEP 1997, vol. 67, no. 2, September 1997 (1997-09), pages 221-233, XP002299274 ISSN: 0166-0934
  • STEELE E J ET AL: "Further evidence for cross-linking as a protective factor in experimental cholera: properties of antibody fragments." THE JOURNAL OF INFECTIOUS DISEASES. AUG 1975, vol. 132, no. 2, August 1975 (1975-08), pages 175-180, XP009037451 ISSN: 0022-1899
  • ISMAIL M ET AL: "Pharmacokinetics of 125I-labelled IgG, F(ab')2 and Fab fractions of scorpion and snake antivenins: merits and potential for therapeutic use." TOXICON : OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY ON TOXINOLOGY. NOV 1998, vol. 36, no. 11, November 1998 (1998-11), pages 1523-1528, XP002299275 ISSN: 0041-0101
  • BEHR T M ET AL: "Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?" CANCER. 15 DEC 1997, vol. 80, no. 12 Suppl, 15 December 1997 (1997-12-15), pages 2436-2457, XP002299276 ISSN: 0008-543X
  • MAYERS CARL N ET AL: "Anti-immunoglobulin responses to IgG, F(ab')2, and Fab botulinum antitoxins in mice." IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, vol. 25, no. 3, August 2003 (2003-08), pages 397-408, XP009037543 ISSN: 0892-3973
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).